Acceptability of coitally-associated versus daily use of 1% tenofovir vaginal gel among women in Pune, India

International Health

Volumn 4, Issue 1, 2012, Pages 63-69

  Mehendale, Sanjay ^a   Deshpande, Swapna ^b   Kohli, Rewa ^b   Tsui, Sharon ^c   Tolley, Elizabeth ^c  

^a National Institute of Epidemiology   (India)

^b NATIONAL AIDS RESEARCH INSTITUTE   (India)

^c FAMILY HEALTH INTERNATIONAL   (United States)

Author keywords

Coital use; HIV AIDS; India; Microbicides; Preventive measures; Vaginal gel

Indexed keywords

TENOFOVIR;

ADULT; ARTICLE; COITUS; CONTROLLED STUDY; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PATIENT DECISION MAKING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SEXUAL BEHAVIOR;

EID: 84857446831     PISSN: 18763413     EISSN: 18763405     Source Type: Journal    
DOI: 10.1016/j.inhe.2011.11.003     Document Type: Article

References (26)

1. US Centers for Disease Control and Prevention. HIV among women. Atlanta, GA: CDC; 2011. [accessed 30 November 2011]. http://www.cdc.gov/hiv/topics/women/pdf/women.pdf.
2. Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS report on the global AIDS epidemic 2010. Geneva: UNAIDS; ©2010. [accessed 30 November 2011]. http://www.unaids.org/documents/20101123_GlobalReport_Chap1_em.pdf.
3. Weller S., Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2002, 1:CD003255.
4. Steiner M.J., Cates W. Condoms and sexually-transmitted infections. N Engl J Med 2006, 354:2642-2643.
5. Reynolds S.J., Shepherd M.E., Risbud A.R., et al. Male circumcision and risk of HIV-1 and other sexually transmitted infections in India. Lancet 2004, 363:1039-1040.
6. Cohen J. Is an effective AIDS vaccine feasible?. Science 2005, 309:99.
7. Alliance for Microbicide Development. Microbicide research and development: pipeline update. Silver Spring, MD: Alliance for Microbicide Development; 6 February 2009.
8. Mantell J.E., Myer L., Carballo-Diéguez A., et al. Microbicide acceptability research: current approaches and future directions. Soc Sci Med 2005, 60:319-330.
9. Morrow K.M., Ruiz M.S. Assessing microbicide acceptability: a comprehensive and integrated approach. AIDS Behav 2008, 12:272-283.
10. Tolley E.E., Eng E., Kohli R., et al. Examining the context of microbicide acceptability among married women and men in India. Cult Health Sex 2006, 8:351-369.
11. Joglekar N.S., Joshi S.N., Kakde M., et al. HIV Prevention Trial Network 047 Protocol Team. Acceptability of PRO2000 vaginal gel among HIV un-infected women in Pune, India. AIDS Care 2007, 19:817-821.
12. Joglekar N.S., Joshi S.N., Navlakha S.N., Katti U.R., Mehendale S.M. Acceptability of Praneem polyherbal vaginal tablet among HIV uninfected women & their male partners in Pune, India-Phase I study. Indian J Med Res 2006, 123:547-552.
13. Han L., Lv F., Xu P., Zhang G., Juniper N.S., Wu Z. Microbicide acceptability among female sex workers in Beijing, China: results from a pilot study. J Womens Health (Larchmt) 2009, 18:1377-1384.
14. Veldhuijzen N., Nyinawabega J., Umulisa M., et al. Preparing for microbicide trials in Rwanda: focus group discussions with Rwandan women and men. Cult Health Sex 2006, 8:395-406.
15. Jones D.L., Weiss S.M., Chitalu N., Bwalya V., Villar O. Acceptability of microbicidal surrogates among Zambian women. Sex Transm Dis 2008, 35:147-153.
16. Ramjee G., Morar N.S., Braunstein S., Friedland B., Jones H., van de Wijgert J. Acceptability of Carraguard, a candidate microbicide and methyl cellulose placebo vaginal gels among HIV-positive women and men in Durban, South Africa. AIDS Res Ther 2007, 4:20.
17. Montgomery C.M., Lees S., Stadler J., et al. The role of partnership dynamics in determining the acceptability of condoms and microbicides. AIDS Care 2008, 20:733-740.
18. Karim A.Q., Karim S.S., Frohlich J.A., et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010, 329:1168-1174. CAPRISA 004 Trial Group.
19. HIV Prevention Trials Network (HPTN). HPTN 059 Phase II expanded safety and acceptability study of the vaginal microbicide 1% tenofovir gel. HPTN; 2008. [accessed 8 December 2009]. http://www.hptn.org/research_studies/HPTN059.asp.
20. National AIDS Control Organization (NACO), Government of India. Mainstreaming HIV and AIDS for women's empowerment. New Delhi: NACO; 2008. [accessed 30 November 2011]. http://www.nacoonline.org/upload/Publication/IEC%20%26%20Mainstreaming/mainstreaming%20hiv%20and%20aids%20for%20women.pdf.
21. Pallikadavath S., Garda L., Apte H., Freedman J., Stones R.W. HIV/AIDS in rural India: context and health care needs. J Biosoc Sci 2005, 37:641-655.
22. Joshi S.N., Joglekar N.S., Ghate M.V., et al. Phase I safety & preliminary acceptability of nonoxynol-9 vaginal pessary as a vaginal microbicide in low risk women in Pune, India. Indian J Med Res 2003, 117:152-157.
23. Bentley M.E., Fullem A.M., Tolley E.E., et al. Acceptability of a microbicide among women and their partners in a 4-country Phase I trial. Am J Public Health 2004, 94:1159-1164.
24. Joglekar N.S., Joshi S.N., Deshpande S.S., Parkhe A.N., Katti U.R., Mehendale S.M. Acceptability and adherence: findings from a Phase II study of a candidate vaginal microbicide, 'Praneem polyherbal tablet', in Pune, India. Trans R Soc Trop Med Hyg 2010, 104:412-415.
25. Joshi S.N., Joglekar N.S., Rochelle D., et al. Comparative acceptability study of the Reality female condom and the version 4 of modified Reddy female condom in India. Contraception 2005, 72:366-371.
26. MTN Microbicide Trials Network. HIV prevention trial of ARV-based strategies to begin next month. Women are focus of VOICE Study testing both a vaginal gel and ARV tablets. Cape Town, South Africa; 20 July 2009. [accessed 29 April 2010]. http://www.mtnstopshiv.org/node/1085.